netFormulary NHS
North Central London
Joint Formulary
 Search
 Formulary Chapter 5: Infections - Full Chapter
Notes:

Prescribing of systemic antimicrobials is 'protected'. All prescribing MUST be in accordance with the Trust Antimicrobial Policy and in conjunction with local antimicrobial guideline:

 Details...
05.03.01  Expand sub section  HIV infection
05.03.01  Expand sub section  Nucleoside reverse transcriptase inhibitors
05.03.01  Expand sub section  Protease inhibitors
05.03.01  Expand sub section  Non-nucleoside reverse transcriptase inhibitors
05.03.01  Expand sub section  Other antiretrovirals to top
Dolutegravir
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NHSE B06/P/a: Dolutegravir for treatment of HIV1 in adults and adolescents
Dolutegravir + Abacavir + Lamivudine
(Triumeq)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
AAAAAAAA

Approved for HIV in line with NHSE Commissioning Policy B06/P/a.

Provider notes

  • NMUH:
    • Non-formulary
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • No restriction stated
 
Link  NHSE B06/P/a: Dolutegravir for treatment of HIV1 in adults and adolescents
Dolutegravir + Rilpivirine
(Juluca)
View adult BNF View SPC online View childrens BNF
Formulary
GP - Red
High Cost Medicine
AAAAAAAA

Approved for HIV in line with NHSE Commissioning Policy 200210P.

Provider notes

  • NMUH:
    • Restricted to HIV team ONLY
  • RFL:
    • Non-formulary
  • RNOH:
    • Non-formulary
  • UCLH:
  • WH:
    • Non-formulary
 
Link  NHSE 200210P: Dolutegravir-rilpivirine for treating HIV-1 in adults
Enfuvirtide
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • To be used in accordance with the London HIV consortium BHIVA guidelines
    • For HIV team only
    • Patients currently benefiting from enfuvirtide in their combination therapy should continue to receive enfuvirtide without interruption. Current benefit is defined as patients whose viral load is either undetectable or remaining below their pre-enfuvirtide baseline level. Patients whose current viral load has substantially rebounded or returned to their baseline level when their first used enfuvirtide and who have a strong CD4 count, are likely to have developed or be developing resistance to enfuvirtide. Enfuvirtide is also unlikely to be having antiretroviral activity, and these patients should consider stopping the enfuvirtide in their combination, with close monitoring BHIVA Guidelines - Treatment of HIV-1 infected adults with antiretroviral therapy
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
 
Maraviroc
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Non-formulary  
  • UCLH:
  • WH:
    • Non-formulary
 
Raltegravir
View adult BNF View SPC online View childrens BNF
Restricted Drug Restricted
GP - Red
High Cost Medicine
AAAAAAAA

Provider notes

  • NMUH:
    • No restriction stated
  • RFL:
    • HIV medicine only
  • RNOH:
    • Restricted for use in accordance with RNOH Sharps Policy and Inoculation Management (see policy)
  • UCLH:
  • WH:
    • For TB / HIV clinic and post-exposure prophylaxis
 
Link  RNOH: Sharps Policy and Inoculation Management
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Homecare
Homecare

Traffic Light Status Information

Status Description

GP - 1st

Medicines suitable for first-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.

  

GP - 2nd

Medicines suitable for second-line use within primary care.

Can be initiated within primary care within their licensed indication, in accordance with nationally recognised formularies, for example the BNF, BNF for Children, Medicines for Children or Palliative Care Formulary. Primary care prescribers take full responsibility for prescribing.

  

GP - Amber

Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.

Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.

Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity.

  

GP - Red

Medicines which should normally be prescribed by specialists only (hospital only).

For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.

See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf

  

GP - Grey

Medicines on hospital formularies which have not been reviewed for suitability in primary care.  

Black

Medicines not recommended for routine use in primary or secondary care.

Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data.

  

netFormulary